Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03310359 · ClinicalTrials.gov registry record · NA
Clinical Trial of Anti-oxidant Astaxanthin in Insulin-resistant Subjects
A NA study, sponsored by University of California, San Diego.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
NCT03310359 is a NA study that has completed, run by University of California, San Diego. The registered enrollment target is 34 participants.
The verdict
NCT03310359, a NA study, has completed, sponsored by University of California, San Diego.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
Study Summary
Astaxanthin is a natural compound, present in many foodstuffs and available as a nutritional supplement that has been shown to have beneficial effects on many of the features of insulin resistance/glucose intolerance, at least in animals. The goal of this project is to provide a validation of astaxanthin effects on metabolic regulation in humans and their mechanism(s) of action, to determine if astaxanthin could have any value as a "neutraceutical" to help improve regulation of glucose and fat metabolism in subjects with insulin resistance/ glucose intolerance.
Interventions
- DIETARY_SUPPLEMENT Astaxanthin
- OTHER Placebo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2016-07 |
| Est. Completion | 2022-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03310359
The ClinicalTrials.gov registry entry for NCT03310359 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Diego, which has 775 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Astaxanthin is the first listed.
NCT03310359 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03310359 about?
NCT03310359 is a clinical study titled "Clinical Trial of Anti-oxidant Astaxanthin in Insulin-resistant Subjects". Astaxanthin is a natural compound, present in many foodstuffs and available as a nutritional supplement that has been shown to have beneficial effects on many of the features of insulin resistance/glucose intolerance, at least in animals. The goal of this project is to provide a validation of astaxa...
What is the current status of trial NCT03310359?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2016-07. Estimated completion is 2022-12-31.
What interventions are being tested in trial NCT03310359?
The interventions under investigation include: Astaxanthin (DIETARY_SUPPLEMENT), Placebo (OTHER).
Who is sponsoring clinical trial NCT03310359?
This trial is sponsored by University of California, San Diego, which has 775 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.